Cell therapy company Mesoblast (ASX:MSB) has entered into a convertible note subscription agreement with its largest shareholder, Gregory George, to issue up to US$50 million convertible notes at its discretion. …
Mesoblast option to issue up to US$50 million convertible notes for product launch
September 30, 2024 Australian Biotech
Latest Video
New Stories
-
Trent Twomey secures second term as Pharmacy Guild national president
September 30, 2024 - - Latest News -
Mesoblast option to issue up to US$50 million convertible notes for product launch
September 30, 2024 - - Australian Biotech -
PolyNovo announces the retirement of long-term non-executive director
September 30, 2024 - - Australian Biotech -
Artrya submits application for Salix to the US FDA
September 30, 2024 - - Other Health -
Budget outcome confirms topline pharmaceutical spend lower than expected
September 30, 2024 - - Latest News -
Good to be inside the tent, but first make sure it's safe to enter
September 30, 2024 - - Latest News -
CSL welcomes scientific community to Australia for global influenza conference
September 30, 2024 - - Latest News